One-carbon therapeutics wins ELAVITY Pitch Event
Our team is happy and proud to have been voted as the winner for pitching our MTHFD1/2 inhibitor program. https://www.linkedin.com/feed/update/urn:li:activity:6948268990171365376
One-carbon therapeutics presents at Bio€quity 2022.
CEO Ana Slipicevic present the MTHFD2 program and one-carbon therapeutics AB in the Hot Topic session at Bio€quity 2022 in Milan.
Pitch prize in Bordeaux
The MTHFD2 program is pitched by CEO Dr Ana Slipicevic at the Meet2Win conference in Bordeaux and wins a pitch price!
Vinnova grants one-carbon therapeutics money
One-carbon therapeutics AB is granted 3,000,000 SEK from Sweden’s innovation agency Vinnova under the Medtech4Health and SweLife programs for further development of the MTHFD2 program.
MTHFD2 inhibitors now published in Nature Cancer
We are proud that the MTHFD2 inhibitors are now published in the prestigious journal Nature Cancer. In this first report, we describe that MTHFD2 inhibitors deplete cells of thymidine, specifically in cancer cells. We show that the loss of thymidine causes replication stress, which is a hallmark for DNA damage response (DDR) inhibitors and placing our […]
One-carbon therapeutics appoints Dr Ana Slipicevic as acting CEO
We are very pleased to announce that Dr Ana Slipicevic has been appointed as acting CEO of one-carbon therapeutics AB. Ana is joining us from Oncopeptides AB where she has been translational research director and leading a team developing and implementing translational research strategies in the early and late-stage clinical trial pipeline. Dr Ana Slipicevic […]
One-carbon therapeutics AB recieves SME status by EMA
One-carbon therapeutics AB receives SME status by EMA The incentives offered by the SME Regulation give access to: Regulatory assistance: SMEs can benefit from direct regulatory assistance including SME briefing meetings, to provide guidance on the EU regulatory framework and the tools to support innovation. Scientific advice: A substantial fee reduction for scientific advice is available […]
Eir Ventures grants one-carbon
Eir Ventures grants one-carbon a convertible loan to continue pre-seed activities in company and at the same time Magnus Persson becomes the new chairman and Alexander Mata joins the board of directors.
One-carbon is receiving a seed investment
One-carbon is receiving a seed investment from its founders to strengthen the financial situation and secure continuous pre-clinical development of MTHFD2 inhibitors.
AACR21 virtual meeting
Prof Thomas Helleday presents MTHFD2 and other emerging targets such as PKMYT1, MTH1 and Pol Theta at the AACR21 virtual meeting.